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Abstract
β1 integrin has been shown to be important for pancreatic beta-cell growth and functioning.
Congenital and postnatal studies have shown beta-cell mass reduction with β1 integrin
knockout (β1KO). Using an inducible cre recombinase (CreERT) expressed from the mouse
insulin promoter (MIP) crossed to a line in which Itgb1 (β1 integrin encoding gene) was
flanked by loxP sites (MIP-CreERT+; β1itg designated as MIPβ1KO), we examined the in
vivo temporal role of beta-cell β1 integrin effect on islet growth during the second transition
stage of pancreas development.
Prenatal MIPβ1KO mice displayed decreased beta-cell area, mass, density and proliferation.
In addition, a decrease in phosphorylated-ERK activity, islet vascularization and nascent
endocrine cells in the ductal region was observed. However, normal levels of transcription
factors needed for beta-cell development was seen. This study may suggest that β1 integrin
plays an important role in prenatal beta-cell development during the second transition stage.

Keywords
β1 integrin, mouse insulin promoter (MIP), tamoxifen-inducible, beta-cell mass, pancreas
development
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Chapter 1 - Introduction
1.1 Significance
The development of the pancreatic and islet of Langerhans requires highly
controlled regulation of transcription factors and signaling pathways necessary for
endocrine cell differentiation, migration, proliferation, and maturation. The interaction
between islet cells and the extracellular matrix through the integrin family is required for
islet beta-cell survival and function. Integrins are also an important factor during the
development of fetal islet cells. To date, the β1 integrin subunit has been shown to affect
islet morphology and function in postnatal murine pancreas. However, the temporal
significance of beta-cell β1 integrin during the second transition stage of pancreas
development has yet to be investigated. This thesis examines the role of β1 integrin
during in utero development of the differentiated beta-cell population. The findings from
this study will improve our understanding of the effects of β1 integrin activity on
developing beta-cells during the second transition stage of embryonic pancreas growth,
which may lead to potential susceptibility towards diabetes postnatally.

1.2 The Pancreas
The pancreas is a glandular organ that consists of a head, neck, body, and tail
region, and is located posterior to the stomach in mice (Gittes, 2009). The pancreas
contributes to both the digestive function and regulation of blood glucose through the
exocrine and endocrine compartments, respectively. The exocrine acinar cells and ductal
system, which secrete digestive enzymes and bicarbonate, respectively, to the duodenum
through the pancreatic duct, make up 97% of total murine pancreatic tissue. Scattered
between the acinar lobules are endocrine cell clusters referred to as the islets of
Langerhans, which contribute to 2-3% of the pancreatic compartment. Murine islets are
primarily made up of a dense core of insulin-secreting beta-cells (β) (~80%) and
glucagon -releasing alpha-cells (a) (~10%) along the islet’s periphery. The other
endocrine cells of the islets are delta (d), epsilon (e), and pancreatic polypeptide (g),
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which releases somatostatin, ghrelin, and pancreatic polypeptide, respectively. The alpha
and beta-cells of the endocrine system work in an antagonistic manner to regulate blood
glucose homeostasis. In response to low glucose levels, glucagon promotes elevated
glycogenolysis from the liver and causes an increase in the circulating glucose level.
Conversely, when glucose levels are high, insulin is released to stimulate insulin
receptor–induced glucose uptake in the skeletal muscle and adipose tissue and promotes
glycogenesis in the liver. To ensure the development of functional glucose-regulating
beta-cells, the embryonic pancreas requires tightly regulated temporal expression of
transcription factors (TF).

1.3 Development of the Murine Pancreas
Murine pancreatic development is divided into the first (embryonic day (e) 8.512.5), second (e12.5-19.5), and third (e19.5-postnatal day (p) 21) transition stages. Each
transition stage requires the timed expression of specific TFs to ensure the proper cell
commitment and maturation of the functional pancreas (Figure 1.1). The detailed
processes of pancreas development are outlined below and includes a brief description of
the major changes to morphology and TF expression in beta-cell development.

1.3.1 Morphological Changes in Pancreatic Development
The region of the foregut endoderm that forms the pancreatic anlage becomes
prominent at e8.5 with evagination of the ventral and dorsal epithelial buds into the
surrounding mesenchyme (Zorn & Wells, 2009). By e10.5, the undifferentiated
pancreatic epithelium is mainly surrounded by mesenchymal tissue and the dorsal
pancreatic bud extends to produce a neck connected to the primitive gut via the central
lumen (Jørgensen et al., 2007). The pancreatic buds at this stage is composed of a
multilayered core with non-polarized pancreatic progenitor cells located throughout the
bed of nascent cells. Shortly after e10.5, the progenitor cells gain apical-basal polarity
and form microlumens (Kesavan et al., 2009). Around e11.5, the primitive gut tube
rotates and fuses the ventral and dorsal buds, forming one pancreatic organ with an
interconnected luminal plexus by e12.5 (Kesavan et al., 2009; Pan & Wright, 2011;
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Villasenor et al., 2010). High levels of cell proliferation also take place during the
formation of this primitive branched tubular structure (Gu et al., 2002; Pictet et al., 1972).
The initial formation of the bud-like microlumen and blood vessels within the ductal
region are also observed at this stage (Magenheim et al., 2011; Pierreux et al., 2010).
Pancreas tubulogenesis begins at the start of the second transition stage (e12.5),
with the apical cell membrane facing the central lumen and the basal cell layer
associating with the extracellular matrix (ECM) (Villasenor et al., 2010). The newly
formed monolayer extensively branches and expands to form a complex network of
tubules from e12.5 until birth (Gittes, 2009). During the branching process, cells located
at the tip of the epithelia tubule form the acinar-committed lobules through adjacent ECM
integrin signaling (Shih et al., 2016). Endocrine precursor cells also differentiate and
migrate from the ductal epithelial cells towards surrounding islet clusters during this
period. This process of endocrine cell neogenesis is observed throughout the second and
third transition stages until p21 (Scaglia et al., 1997). By e14.5, the extensive pancreatic
plexus has remodeled toward a single lumen (pancreatic duct) to support unidirectional
tubule flow towards the duodenum (Villasenor et al., 2010). By the end of the second
transition stage, the pancreas had been organized into defined exocrine and endocrine
compartments.
The third transition stage of murine pancreas development involves the
remodeling of a structurally organized pancreas. Most of the exocrine cells are
aggregated near the ductal network with the islets distributed throughout the pancreas
(Pictet et al., 1972). Development from e19 to p21 results in a gradual decrease of betacell neogenesis from the ductal epithelium and the replication of pre-existing cells
becomes responsible for formation of new beta-cells (Dor et al., 2004). This remodeling
stage ensures the robust formation of beta-cells with the ability to manage glucose
homeostasis in the mature pancreas (Hill, 2005).
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Figure 1.1: A schematic of important time points during islet development in mice.
Mouse pancreatic development is divided into the first (e8.5-e12.5), second (e12.5e19.5), and third (e19.5-p21) transition stage. Beta-cell neogenesis occurs throughout
prenatal and neonatal pancreas development, but declines after the neonatal period with
replication becoming the main source of postnatal beta-cell growth.
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1.3.2 Transcription Factors in Pancreatic Development
Several TFs are involved in the development of both exocrine and endocrine
lineages in the pancreas, yet this section will focus solely on the major TFs involved in
beta-cell formation (Figure 1.2).
The first transition stage at e8.5 is characterized by the high expression of
pancreatic duodenal homeobox 1 (Pdx-1), pancreas-specific transcription factor (Ptf1a),
and SRY box 9 (Sox9) throughout the epithelial layer of the dorsal and ventral pancreatic
buds (Burlison et al., 2009; Kawaguchi et al., 2002; Seymour & Sander, 2011). These
three TFs are important in determining murine pancreatic fate during early development
since pancreatic hypoplasia occurs with the absence of any one of the three TFs (Gittes,
2009). Early expression (e9) of the LIM homeobox TF islet-1 (Isl1) is required in the
pancreatic endoderm for subsequent generation of endocrine cells, and ablation of the
Isl1 gene causes a near complete lost of the pancreatic mesenchyme and reduction of
Pdx-1 expression in the developing embryo (Ahlgren et al., 1997; Du et al., 2009). The
expression of Ptf1a, Forkhead box O1 (FoxO1), Nk2 homeobox 2 (Nkx2.2), and Nk6
homeobox 1 (Nkx6.1) shortly follow the expression of Pdx-1 (Hald et al., 2008; Kitamura
et al., 2009; Sander et al., 2000). Initial signs of endocrine differentiation are also seen
during the first transition stage with the controlled expression of neurogenin 3 (Ngn3).
Ngn3 is an important marker for endocrine precursor cells, yet these early first transition
endocrine cells do not contribute to the adult islets (Pan & Wright, 2011). In contrast to
the first transition stage, beta-cells formed in the second transition contribute to
functioning mature islets (Gunasekaran et al., 2012).
During the second transition stage, multipotent progenitor cells begin their
commitment and differentiation towards an endocrine, acinar, or ductal cell fate by
adopting either a tip or trunk confirmation based on signaling through the membrane
receptor Notch (Afelik & Jensen, 2013; Nielsen et al., 1999). The presence of TFs Ptf1a
and c-Myc with pancreatic enzyme carboxypeptidase A (Cpa) marks the tip domain,
which eventually gives rise to the exocrine (acinar cells) portion of the pancreas. The
extending trunk compartment, which gives rise to ductal and endocrine cells, expresses
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Nkx6.1/6.2, Sox9, Tcf2, Onecut-1, Prox1, and Hes1 (Jacquemin, et al., 2003; Kopinke et
al., 2011; Schaffer et al., 2013; Zhou et al., 2007). Controlled expression of Notch
regulates the trunk compartment differentiation towards either a ductal or endocrine cell
fate. When Notch is up-regulated, Hes1 represses Ngn3 and promotes ductal cell fate
(Afelik & Jensen, 2013). Down-regulation of Notch signaling leads to decreased Hes1
expression, allowing for Ngn3 expression to emerge in Sox9+ cells. Ngn3 marks the
earliest progenitor of all endocrine cells in pancreas development and is central for the
expression of other TFs that determine beta-cell lineage differentiation (Gradwohl et al.,
2000). Once Ngn3 expression is initiated, Ngn3+ cells delaminate and migrate away from
the surrounding Sox9+ ductal tissue compartment into the mesenchyme for the initial
formation of the endocrine clusters (Gradwohl et al., 2000; Johansson et al., 2007;
Schwitzgebel et al., 2000).
Nkx6.1 expression is required for beta-cell lineage during the second transition
stage, where it promotes both beta-cell gene activation and down-regulation of TFs
associated with other endocrine genes (Schaffer et al., 2013). The TFs
musculoaponeurotic fibrosarcoma homolog A (MafA), paired box 4 (Pax4), and
neurogenic differentiation 1 (NeuroD1) are also important during beta-cell differentiation
and are essential for survival in the emerging mature beta-cell (Collombat et al., 2003,
2009; Nishimura et al., 2006; Yang et al., 2011).
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Figure 1.2: Simplified model of pancreatic progenitor cell differentiation in the
developing mouse pancreas
Only major factors associated with the development of beta-cells are shown. The
coloured shapes represent the differentiating cell types.
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1.4 Islet Vascularization
Although the endocrine compartment only contributes to 2% of the mature
pancreas mass, almost 10-15% of the total pancreatic blood vessels from the coeliac and
superior mesentery arteries vascularize the islet of Langerhans (Henderson & Moss,
1985; Jansson & Hellerström, 1983). Islet vascularization is essential for the regulation of
hormone secretion and blood glucose monitoring. High levels of vascular endothelial
growth factor-a (Vegf-a) are observed in the beta-cells (Brissova et al., 2006; Watada,
2010). Vegf-a increases angiogenesis during development through endothelial cell
recruitment and aids in maintaining the islet vasculature in postnatal pancreata
(Christofori et al., 1995; Reinert et al., 2013).
Early signs of pancreatic perfused capillaries are observed at e10.5 and integration to the
surrounding peripheral capillary bed as epithelial branching begins around e11.5-12.5
(Pierreux et al., 2010; Shah et al., 2011). Ablation of blood vessels in the developing
pancreatic bud, which can be induced through either aorta removal before bud formation
or inhibition of Vegf receptor after budding, leads to the absolute failure of pancreas
growth (Lammert et al., 2001; Magenheim et al., 2011). Importantly, vascular endothelial
cells in the islets are responsible for the production of the basement membrane. Beta-cell
proliferation is affected through the interaction of β1 integrin and the laminin ligand of
the endothelial cell basement membrane (Nikolova et al., 2006). Additional work has
found that the ECM interacts with islet vasculature to decrease the levels of intraislet
endothelial cell death (Van Deijnen et al., 1992). Another in vivo study that subjected
mice to subcutaneous transplantation of fibrin-enriched islets showed an increase in islet
vessel count and neovascularization (Sabek et al., 2010). These studies demonstrate an
interaction network between the islet vasculature, ECM, and β1 integrin that maintains
islet vascularization and survival.

1.5 Diabetes Mellitus
Diabetes mellitus is a metabolic disorder where the body does not produce insulin
or improperly utilize the endogenous insulin. This in turn could cause elevated blood
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glucose level which may potentially harm blood vessels, nerves and organs.
Hyperglycemia develops due to abnormal insulin production and/or the emergence of
peripheral insulin resistance. Type 1 diabetes (T1D) is caused by an autoimmune
response by the T-cells towards insulin producing beta-cells. As a result, T1D patients
lose the majority of functional beta-cell mass and rely on an exogenous insulin source to
regulate glucose levels. In contrast, the pathogenesis of type 2 diabetes (T2D) can arise
from multiple factors that result in a hyperglycemia-induced compensatory insulin
production response and peripheral tissue insulin resistance. The general onset of T2D
are slower to progress and primarily in inactive obese adults with the initial reduced
sensitivity to insulin. The beta-cells initially expand as a compensatory mechanism but
eventually fail with the prolonged demand for insulin, leading to reduced beta-cell mass
and insulin production. Various treatments are available for T2D patients, including
pharmaceutical and lifestyle management in diet and reduction of body weight. However,
late-stage cases may eventually require exogenous insulin.
The Edmonton protocol, first established at the University of Alberta, was designed to
restore functional beta-cell mass to T1D patients by transplanting healthy isolated islets
from cadaver donors into the hepatic portal vein of immunosuppressed recipients. This
treatment has shown promising success in inducing short-term (1-5 years) insulin
independence in patients, yet most islet recipients revert back to insulin dependence after
five years due to multiple factors, with recurring autoimmune responses and allograft
rejection as the main factors behind their loss in insulin independence (Shapiro, 2012).
This protocol is also limited by the lack of donors and the success rate of isolating a
sufficient number of healthy islets (Shapiro et al., 2000). Common issues that arise from
removing donor islets from their micro-environment are the disruption of vasculature, the
development of reduced beta-cell mass and function, and the promotion of islet cell death
(Ryan et al., 2005). Additional difficulties that occur with prolonged cultures of isolated
islets ex vivo are a high level of senescence, loss of the islet architecture, and a reduction
in insulin expression (Halvorsen et al., 2000). A possible solution to extend islet survival
would be to design an islet micro-environment that optimizes islet cell-ECM interactions.
Integrin receptors are one of the major receptors that regulate key cell-ECM
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communication pathways and adhesion, and optimizing their expression in islets could
lead to improved viability and insulin secretion.

1.6 Integrin and ECM
1.6.1 ECM
Integrin function is dependent on its extracellular attachment to the ECM. The
ECM is a highly dynamic non-cellular component found ubiquitously in all organs. It
provides a physical scaffold and essential biochemical signals required for cell
differentiation, survival, and morphological architecture (Frantz et al., 2010; Shih et al.,
2016; Stendahl et al., 2009).
The arrangement and composition of the ECM differs slightly among tissue types.
However, the core function in providing cellular support remains constant among
different tissue. Proteoglycans and fibrous proteins make up most of the ECM and forms
a hydrated gel that fills the interstitial space (Stendahl et al., 2009). Fibronectins,
laminins, collagens, and vitronectin (VN) are the main ECM adhesion protein in the
pancreas, and each protein serves as a specific ligand through which integrin receptors
will bind to.

1.6.2 Integrin
Integrins are a family of cell adhesion receptors that interact with the ECM and
incorporate both extra- and intracellular processes. Integrins are composed of an a and b
subunit. There is a small cytoplasmic tail of less than 50 amino acid and an ectodomain
protein size of about 1200 amino acids for the a subunit and 800 amino acids for the b
subunit (Bouvard et al., 2001; Humphries et al., 2012). The family of mammalian
integrins consist of 18a and 8b subunits that can combine to 24 unique heterodimeric
forms of integrin (Takada et al., 2007). Each heterodimeric integrin complex has a
different degree of affinity towards various ECM ligands and are categorized based on
their affinities. The extracellular ligand –binding a subunit stimulates intracellular
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cytoskeletal remodeling and signaling through the b subunit (‘outside-in’), while
signaling cues through the b subunit leads to a subunit (‘inside-out’) (Barczyk et al.,
2010; Takada et al., 2007). Nuclear magnetic resonance spectrometry has shown a
combination of electrostatic and hydrophobic interactions between the cytoplasmic tails
of the α and β integrin subunits that regulate inside-out signaling (Qin et al., 2004; Ulmer
et al., 2001; Vinogradova et al., 2002; Weljie et al. , 2002).
b1 associates with a3, a6, a7, a5, aV, and a8 to selectively bind to the laminin (LM)
and fibronectin (FN) group of glycoprotein containing the Arg-Gly-Asp (RGD) motif in
their structure (Minton, 2013). b2 integrin primarily associates with aL, aM, aX, and
aD, which allows for leukocytes in the extracellular matrix to interact with endothelial
cells and deliver a diverse range of cellular responses (Harris et al., 2000). Even with the
existence of multiple different classes of integrin, there is a large overlap in ligand
binding preference. Therefore, there is no limitation towards binding to a single specific
ligand type (Boudreau & Jones, 1999; Lee & Juliano, 2004). This overlap in numerous
ligand preferences depends on integrin affinity, which is determined based on if the
heterodimer is in an inactivated (low-affinity) or activated (high-affinity) conformation.
The major integrin -associated downstream nonreceptor adhesion complex of focal
adhesion kinase (FAK) facilitates the activation of intracellular signaling pathways,
including the protein kinase B (Akt) and Ras pathways. FAK directly binds with the
actin-binding protein talin and kindlin, which are both important in activating and linking
integrin to the actin cytoskeleton. Inside-out signaling begins with talin binding to the
cytosolic domain of the b integrin subunit. This activates the kindlin protein family,
which in turn changes the integrin into a high-affinity conformation (Shattil et al., 2010).
The accessible high-affinity state of the integrin allows for extracellular ligand binding,
promoting outside-in signaling and an additional cascade of downstream integrin associated pathways (Takagi et al., 2002).
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1.7 β1 integrin subfamily
β1 integrin associates with 12 different types of α subunits (α1- α11 & αV),
making it the largest subfamily of integrins with different ligand binding specificity
(Barczyk et al., 2010; Fassler & Brakebusch, 2005). The association of β1 integrin with
different α subunits is highlighted in Figure 1.3 (Gahmberg et al., 2010). The
cytoplasmic domain contains the highly conserved NPxY motif responsible for
controlling inside-out activation. The cytoplasmic tail of β1 integrin does not contain an
actin binding site or any enzymatic capabilities. Instead, attachment to the actin
cytoskeleton for β1 integrin is mediated by four different protein complexes of α-actinin,
talin, filamin, and integrin linked kinase (ILK) (Fassler & Brakebusch, 2005).
Several key signaling pathways of the FAK/MAPK/ERK and PI3K/Akt are mediated by
β1 integrin and have been confirmed in a variety of studies using both in vivo and in vitro
models (Hammar et al., 2004; Peart et al., 2017; M. Riopel et al., 2011; Saleem et al.,
2009). It is through this bi-directional signaling pathway in which β1 integrin controls
cell proliferation, differentiation, and survival. (Cordes et al., 2006; Wennerberg et al.,
2000). These intracellular protein complexes act as a binding platform for other
cytoskeletal and signaling molecules.
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Figure 1.3: β1 associations with α integrin subunits.
α subunits highlighted with red indicate the major integrin associations that are involved
in islet development with their preferred ECM ligand binding partner. α subunits
highlighted with blue indicate integrin association found outside the beta-cells. (VN=
Vitronectin, FN= Fibronectin, LM= Laminin) (Adapted from Gahmberg et al., 2010)
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1.7.1 β1 integrin in pancreas development
Early studies have shown the lethal effect of β1 integrin gene ablation during
morphogenesis, where the inner cell mass fails to form in the late blastocyst stage
(Stephens et al, 1995). In vitro work that assessed the role of β1 integrin during pancreas
development has shown that isolated human fetal islets at 19-21 weeks of gestational age
preferentially adhered to a collagen IV matrix through integrin α1β1, and a similar
pattern was observed with fetal beta-cell adhesion to vitronectin through αVβ1 integrin
(T. Kaido et al., 2004). Previous studies from our lab have shown the effect of β1 integrin
on islet cell survival, maturation, and proliferation during pancreas development in both
rat and human models. The developing endocrine cells in the human and murine pancreas
express integrins α3β1, α5β1, and α6β1, with increased levels of mRNA and protein for
these integrin heterodimers by 16-20 weeks and e18-p21 days, respectively (Yashpal et
al., 2005).
The role of β1 integrin receptor during pancreatic development was further studied using
an immunoneutralizing blocking antibody, and this resulted in inhibited adhesion of
cultured fetal human and rat islets to collagen I, fibronectin, and laminin matrices.
Blocking β1 integrin also reduced Insulin mRNA levels and increased islet cell death in
both rat and human models (Wang et al., 2005; Yashpal et al., 2005). Similar to the β1
integrin blocking study, subsequent studies that specifically blocked the a3 subunit
demonstrated inhibited human fetal islet cell adhesion to collagen I and IV matrices, with
reduced proliferation and Pdx-1 and insulin expression (Krishnamurthy et al., 2011).
However, the PI3K/Akt pathway was only affected by a3 blockade and not β1 blockade,
indicating that signaling pathways are specific to different integrin subunits during early
human development. As mentioned, β1 integrin has also been shown to be involved in
the FAK/MAPK/ERK downstream signaling pathway in human fetal pancreatic islet cells
(Saleem et al., 2009).
The study of a rat insulin (insulin 2) promoter β1 integrin knockout mouse model
(RIPβ1KO), which results in the loss of β1 integrin specific to developing mouse betacells, showed a significant reduction in beta-cell mass, indicating that β1 integrin
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promotes expansion of the beta-cell compartment (Diaferia et al., 2013). In addition,
global gene expression analysis revealed reduced expression of genes that function as
positive regulators of cell cycle progression. The findings from this study indicate that the
interactions between the ECM and beta-cell β1 integrin play an important role in ensuring
sufficient islet proliferation and expansion during pancreatic development.

1.7.2 β1 integrin in islet survival and function
Formative in vitro work that looked at β1 integrin’s role in islet survival was
completed using the RIN-2A cell line, originally derived from rat islet cells (Kantengwa
et al., 1997). Both the primary and transformed cells showed the presence of β1 integrin,
and blocking β1 integrin led to a reduction in cell spreading and attachment to the ECM
(Kantengwa et al., 1997). A follow-up immunodepletion study indicated that the α3β1
heterodimer constituted approximately half of total β1 integrin expressed in the primary
rat islet cells. Isolated islets also require β1 integrin-ECM interactions to promote their
survival in vitro. The survival of isolated islet cells was vastly improved when cultured
with collagen I and fibronectin, which are prominent ligands of β1 integrin. Anti-β1
integrin antibody treatment in isolated rat islets on tumor derived basement membrane
producing 804G matrix resulted in reductions for both beta-cell spreading and
phosphorylation of focal adhesion kinase (Parnaud et al., 2006). In addition, the
spreading of beta-cells was also reduced when the interaction between β1 integrin and
laminin-5 was blocked, which led to a lower level of insulin release. The 804G matrix
protected against beta-cell apoptosis through the increased activation of the
FAK/MAPK/ERK1/2 pathway (Hammar et al., 2004).
Insulinoma-1 (INS-1) cells, derived from irradiated rat insulinoma cells, have been
extensively utilized in literature due to their functional characteristics that mirror
pancreatic beta-cells, including their similar physiological release of insulin in response
to glucose stimulation (Asfari et al., 1992; Skelin et al., 2010). α3β1 is highly expressed
in INS-1 cells, but other β1 integrin associations (α1-α6 and αV expression) have also
been identified (Krishnamurthy et al., 2008). Culturing the INS-1 cells on collagen I and
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IV also significantly increased spreading, proliferation, adhesion, and FAK
phosphorylation, while blocking α3β1 integrin diminished these effects.
The generation of different knockout mouse models has allowed for investigation into the
role of β1 integrin on adult islet physiology and interactions between the ECM and betacells. A conditional knockout mouse model of β1 integrin in collagen 1a2 (col1a2)producing cells, commonly expressed in connective tissue, bone, and tendon, was
developed (β1KO mice) (Riopel et al., 2011). This model utilized the tamoxifen –induced
CreERT-loxP system to knockout β1 integrin at 3 weeks of age. Adult male β1KO mice
developed glucose intolerance, reduced beta-cell mass and proliferation, and increased
beta-cell apoptosis (Riopel et al., 2011). Decreased phosphorylation of FAK and ERK
were also shown in β1KO islets, indicating that the loss of β1 integrin negatively affected
FAK/MAPK/ERK signaling required for beta-cell function. Furthermore, β1KO islets
physically dissociated from surrounding exocrine tissue, demonstrating the involvement
of β1 integrin towards maintaining endocrine architecture in vivo. However, the model
was limited in its study of beta-cell -specific β1 integrin loss since the knockout was not
exclusively localized to beta-cells.
The RIPβ1KO mouse model (β1 integrin knockout specific to the beta-cells by rat insulin
promoter) produced a reduction in beta-cell mass in adult mice (Diaferia et al., 2013). In
contrast to the previous study that induced knockout at adulthood, the β1 integrin
knockout in RIPβ1KO mice is present as soon as the Ins-2 gene is expressed at e8.0
during pancreas development (Diaferia et al., 2013; Jiang et al., 2010). Similar to
previous in vitro studies, isolated RIPβ1KO pancreatic cell clusters had impaired
adhesion to the 804G matrix. Even though a significant reduction of beta-cell mass was
noted in mice at 8 weeks, RIPβ1KO mice did not develop a diabetic phenotype and
displayed normal glucose responses. This study suggested that this may be due to
compensatory upregulation through other β subunits, including β3, β4, and β5 integrin
receptors.
A more recent study using a postnatally -induced mouse insulin promoter (MIP)-CreER
knockout of β1 integrin in beta-cells (MIPβ1KO) demonstrated impairments in glucose

17

tolerance and a reduction in beta-cell mass, islet density, insulin release, and beta-cell
proliferation in male adult mice 8 weeks post-induction (Peart et al., 2017).
Phosphorylation of signaling molecules FAK, ERK, and Akt were reduced in isolated
MIPβ1KO islets. Furthermore, MIPβ1KO female mice similarly developed glucose
intolerance after 16 weeks post-induction. These findings are consistent with the findings
from the inducible col1a2 promoter β1KO mice. Unlike the earlier β1KO and RIPβ1KO
studies, inducible MIPβ1KO mice are an improved appropriate model for temporal
control of beta-cell specific loss of β1 integrin. However, the compensatory response
postulated in the RIPβ1KO study was not observed in MIPβ1KO mice. These
discrepancies may be due to a specific temporal role of beta-cell β1 integrin during betacell development and maturation, and thus emphasizes the need for an in vivo mouse
model with an inducible beta-cell specific knockout of β1 integrin.
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1.8 Rationale, Objective and Hypothesis
Proper pancreas growth and remodeling is crucial for the development of
functional beta-cells that maintain glucose metabolism. Pancreatic islet development is
enriched by the dynamic interaction between the ECM and integrin receptors. Previous
studies have suggested the importance of β1 integrin in pancreas embryogenesis.
Although reduced postnatal beta-cell mass was noted in all mouse models with β1
integrin knockout, the presence of glucose intolerance differed between models based on
the stage of beta-cell development that β1 integrin was lost (Diaferia et al., 2013; Peart et
al., 2017; Riopel et al., 2011). In contrast to the RIPβ1KO study, this project will use a
tamoxifen-inducible β1 integrin knockout model with Cre recombinase downstream to
the mouse insulin promoter (MIP). The use of MIP over RIP –driven recombination will
eliminate the potential off-target knockout of β1 integrin in the RIP -expressing
hypothalamic tissue (Tamarina et al., 2014; Wicksteed et al., 2010). The proposed study
will examine inducing beta-cell β1 integrin knockout at the start of the second transition
stage of pancreas development, a window for major beta-cell differentiation and
proliferation during the development. This is in contrast to previous study where
knockout was induced in adult mice.

Objective
To determine the role of β1 integrin in mouse fetal pancreatic beta-cell
differentiation, proliferation, and survival during the second transition stage of pancreas
development.

Hypothesis
The ablation of β1 integrin in beta-cells at the second developmental transition
stage will impair beta-cell differentiation, migration, and proliferation.
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Specific Questions
1. Does the frequency of tamoxifen administration affect the percentage of β1
integrin knockout in MIPβ1KO beta-cells?
2. Does a beta-cell specific β1 integrin knockout perturb beta-cell proliferation and
apoptosis at the end of the second transition stage?
3. Is beta-cell formation from the ductal compartment affected in MIPβ1KO mice?
4. Does the expression of beta-cell specific transcription factors and signaling
change in MIPβ1KO mice?
5. Is islet vascularization affected in MIPβ1KO mice?
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Chapter 2 – Material and Methods
2.1 Generation of temporally -induced fetal MIPβ1KO mouse
model
B6;129-Itgb1tm1Efu/J (β1itgfl/fl) and Tg(Ins1-Cre/ERT)1Lphi (MIP-CreERT) mice
were obtained from Jackson Laboratories (Bar Harbor, MA, USA; stock number:
004605) and Dr. Louis Philipson’s laboratory (University of Chicago, Chicago, IL,
USA), respectively, and crossed to produce heterozygous MIP-CreERT+/-; β1itgfl/+ mice
(Peart et al., 2017). MIP-CreERT mice were crossed with the B6.CgGt(ROSA)26Sortm9(CAG-tdTomatro)Hze/J reporter mouse line (stock number: 007909, Jackson
Laboratories, Bar Harbor, ME, USA) to confirm that Cre recombinase activity was
specific to beta-cells (Trinder et al., 2016). MIP-CreERT+/-; β1itgfl/+ mice were further
crossbred to produce both tamoxifen-inducible β1 integrin knockout (MIPβ1KO, MIPCreERT+; β1itgfl/fl) and control (Control, MIP-CreERT-; β1itgfl/fl and MIP-CreERT+;
β1itg+/+) offspring (Figure 2.1).
Tamoxifen (³99%, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% ethanol
at 60oC. For ease of delivery and dilution purposes, corn oil (Sigma-Aldrich) was mixed
with ethanol-dissolved tamoxifen to yield a final concentration of 30 mg/mL. Tamoxifen
was administered at 6 mg/ 40 g of body weight (BW) through oral gavage to pregnant
heterozygous or mutant MIPβ1KO dams during the 2nd transitional stage of fetal pancreas
development (Figure 2.2). The tamoxifen dosage frequency was subsequently increased
to three doses (3x) for three consecutive days from e13.5-15.5. Due to the high fetal
toxicity observed with 3x tamoxifen administration, the dosage was reduced to two doses
(2x) administered at e13.5 and e15.5.
Fetuses were collected from euthanized pregnant mothers at e19.5. Fetal body weights
were recorded and tail snips were collected for genotyping. Pregnant mice were initially
given a single dose of tamoxifen (1x) at e13.5, but low β1 integrin knockout levels were
observed through histological quantification (Figure 3.4A). Pancreata were dissected and
weighted from all pups for protein extraction or histological analysis. Tamoxifen induced
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fetal pancreas collection was done using control samples from controls (MIP-CreERT-;
β1itgfl/fl and MIP-CreERT+; β1itg+/+) and the experimental MIPβ1KO (MIP-CreERT+/-;
β1itgfl/+). Fetus blood samples were also collected for measuring glucose and insulin
levels. An enzyme linked immunosorbent assay (ELISA) kit (ALPCO, Salem, NH, USA)
was used to measure circulating plasma insulin content.
All protocols were approved by the Animal Use Subcommittee at the University of
Western Ontario in accordance with the guidelines of the Canadian Council of Animal
Care (Appendix I). All mice were allowed ad libitum access to food (Irradiated 2919,
Harlan Tekard, Indianapolis, IN, USA) and water in a constant ambient temperature of
20oC with 12-hour day/night cycles.
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Figure 2.1: Breeding strategy for generation of MIPβ1KO mice.
Generation of crossing MIP-CreERT+ mice with B6;129-Itgb1tm1Efu/J to produce
heterozygous MIP-CreERT+/-;Itgb1fl/+ breeding pairs. The experimental mice are either
MIPβ1KO (MIP-CreERT+;Itgb1fl/fl, red) or controls (MIP-CreERT+;Itgb1+/+ and MIPCreERT-;Itgb1fl/fl, blue) (Peart et al., 2017). The expected frequency of offspring from
MIP-CreERT+/-;Itgb1fl/+ pairs, with the expected experimental genotypes displayed
below.

fl/fl
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Figure 2.2: Schematic of beta-cell β1 integrin knockout (MIPβ1KO) in accordance
with important pancreas development stages in developing murine embryos.
The three transitional stages in mouse pancreas development are outlined above with the
start at embryonic day 8.5 (e8.5). Pregnant females were administered different
tamoxifen dosages via oral gavage between e13.5-e15.5. Fetal mice were dissected for
pancreas collection at e19.5.
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2.2 Genotyping of the MIPβ1KO mouse line
Tail samples from fetal (e19.5) mice were incubated in base solution (25 mM
NaOH; 0.2 mM ethylenediaminetetraacetic acid) and heated for 30 minutes at 95°C for
DNA extraction. 40mM Tris-HCL (pH 5.5) was subsequently added to neutralize the
solution. 1 µL of each DNA sample was used to perform a 26-cycle polymerase chain
reaction (PCR) with primer pair of MIP& CreER and oIMR1906 & oIMR1907 primers
(Table 1). PCR products were determined using gel electrophoresis (1.5% agarose gel
stained with ethidium bromide) and were visualized using the Gene Genius Bio Imaging
System (SynGene, Frederick, MD, USA) and GeneSnap 7.12 software (SynGene;
Cambridge, England). Bands at 268 base pairs (bp) were observed in MIPCreERT+ mice.
Genotypes for the β1itg PCR product were obtained based on the DNA fragment size:
160bp alone (β1itg+/+), 280bp alone (β1itgfl/fl), or at both 160bp and 280bp (β1itgfl/+)
(Figure 2.3).
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fl/fl

Itgβ1 (280bp)
+/+
Itgβ1 (160bp)

Figure 2.3: PCR genotyping of fetal mice
(A) Band products for MIPCreERT+ mice (268 bp). The absence of a band at 268 bp
denotes a MIPCreERT - (blue box) mouse. (B) Itgβ1 mice homozygous for floxed alleles
at 280bp (Itgβ1fl/fl, red arrow), homozygous for wildtype alleles at 160bp (Itgβ1+/+, blue
arrow), or heterozygous for both the wildtype and floxed allele with two bands at 160bp
and 280bp (Itgβ1fl/+, green arrow).
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2.3 Tissue processing and histological analyses
Fetal pancreata were fixed in 4% paraformaldehyde (PFA) overnight at 4o C.
Pancreata were embedded in paraffin wax following a series of dehydration steps using
ethanol and toluene gradients (Shandon CitadelTM Tissue Processor, Citadel 1000,
Thermo Electron Corporation; Waltham, MA, USA). The entire length of the pancreatic
blocks were cut into single sections at a thickness of 4 µm using a microtome (Leica
RM2245, Leica Biosystems). Tissue sections were dried on a 37o C slide warmer
chamber overnight.
For immunofluorescence and immunohistochemical staining, sections were deparaffined
in a series of xylene and ethanol washes. Heat-induced antigen retrieval was conducted
using a sodium citrate antigen retrieval solution (pH 6.0). To prevent non-specific
antibody binding, slides were treated with blocking solution containing 10% goat serum
(Invitrogen; Carlsbad, CA, USA) for 30 minutes at room temperature. Sections were
stained using primary antibodies with their indicated dilution (Table 2) and incubated
overnight at 4o C. For immunofluorescence staining, fluorescein isothiocyanate (FITC)
and tetramethyl rhodamine isothiocyanate (TRITC) conjugated secondary antibodies
(Jackson Immunoresearch Laboratories; West Grove, PA, USA) were used at a 1:50
dilution (Table 2). 4'-6'-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) counterstain
was administered to label cell nuclei. Visualization was done using a Leica LMIRE2
fluorescence microscope and Image ProPlus software (MediaCybernetics).
Immunohistochemical staining utilized a streptavidin-biotin horseradish peroxidase
secondary antibody complex with aminoethyl carbazole substrate (Invitrogen) after initial
incubation of primary antibodies. Hematoxylin was used to counterstain for cell nuclei.

2.4 Morphometric analysis of histological sections
Morphometric analysis of the islets in fetal tissue sections were done using Image
ProPlus software (MediaCybernetics). An islet was defined as a group of cells with at
least three or more insulin+ cells and one glucagon+ cell. For quantification of islet
density, islet number per pancreatic section was counted and divided to the total pancreas
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area and data were expressed as islet number per mm2. Islet area was determined by
manually tracing all the islets on the section for each experimental sample. The percent
islet area was calculated by the total islet area over the total area of the pancreas section.
For measurement of beta cell and alpha cell mass, manually tracing insulin+ or glucagon+
areas were performed and calculated as follows: alpha or beta cell mass (mg) = [beta or
alpha cell area x pancreas mass (mg)]/pancreas area (Wang et al. 1994).
The presence of transcription factors in ductal and beta cells was conducted using double
immunofluorescence staining for Pdx-1 or insulin with pan-cytokeratin (pan-CK),
respectively. Quantification was completed by manually counting the total number of
double positive cells in the total pan-CK+ or insulin+ cell populations.
Islet microvasculature was labeled using the endothelial cell marker platelet endothelial
cell adhesion molecule (PECAM-1). Sections were co-stained with insulin to visualize
capillaries in the islets. Total islet capillary area (PECAM-1+/insulin+) was manually
traced and divided over total insulin+ area. The islet capillary density was measured by
tabulating the total number of islet capillaries over the total islet area. All islets on a
section were analysed and a minimum of four pancreata per experimental group was
used.

2.5 Protein extraction and western blot analyses
Fetal pancreata were sonicated in Nonidet-P40 lysis buffer (Nonidet-P40,
phenylmethylsulfonyl fluoride, sodium orthovanadate) (Sigma-Aldrich) containing a
completeTM protease-inhibitor coctait tablet (Roche Applied Science, Quebec City, QC,
Canada). Samples were spun down for 20 minutes at 4oC and supernatants were stored at
-80 OC. Protein concentration was determined using a Bradford assay with Bio-Rad dye
reagent (Bio-Rad Laboratories, Mississauga, ON, Canada). The absorbance of the
microtiter plate was read at 595nm using a Multiskan Spectrum spectrophotometer
(Thermo Scientific). Protein lysates were loaded at an equal concentration (15-20 µg) per
well on either a 5, 7.5, 10, or 12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE)
running gel. Gels were transferred onto nitrocellulose membranes (Bio-Rad
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Laboratories), and the transfer process was done in a cold chamber with transfer buffer
composing of glycine (192 mM), Tris (25 mM), and methanol (20% v/v) at a constant
current of 250 mA for 180 minutes. Ponceau S stain was applied to the nitrocellulose
membrane and the gels were treated with Coomassie blue followed by destaining solution
to assess the quality of protein transfer. Membranes were washed in Tris buffered saline
with 0.1% Tween-20 (TBST) solution and blocked in a 5% non-fat dry milk blocking
solution for 1 hour at room temperature to prevent non-specific binding. Membranes
were treated with diluted primary antibodies (Table 1) at room temperature for 2 hours or
overnight at 4oC. Secondary anti-rabbit or anti-mouse horse radish peroxidase conjugated antibody (Cell Signaling; Temecula, CA, USA) was applied for 1 hour at
room temperature before visualization with a chemiluminescence ECLTM-Plus Western
Blot detecting reagent (PerkinElmer, Wellesley, MA, USA). Images were taken using the
Versadoc Imaging System (Bio-Rad Laboratories) and Quantity One software (Bio-Rad
Laboratories). The protein of interest was normalized to the loading control protein on the
same membrane. Imaged protein bands on the membrane were quantified using
densitometric analyses with Image Lab 3.0 software (Bio-Rad Laboratories).

2.6 Statistical Analysis
Data is presented as means ± SEM with data of n ³ 3 or means ± SD with data of
n=2. Statistical analysis was done using a two-tailed unpaired Student’s t-test with
GraphPad Prism 6 (GraphPad software; La Jolla, CA, USA). Differences were considered
statistically significant when p<0.05.
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Table 1: List of Primers used for Polymerase Chain Reactions
Primer Name

Primer Pair Sequence

oIMR1906

5’-CGG CTC AAA GCA GAG TGT CAG TC-3’

oIMR1907

5’-CCA CAA CTT TCC CAG TTA GCT CTC-3’

MIP

5’- CCT GGC GAT CCC TGA ACA TGT CCT - 3’

CreER

5’- TGG ACT ATA AAG CTG GTG GGC AT - 3’
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Table 2: Primary and Secondary antibodies used for Immunostaining and WesternBlot Analysis.
Primary Antibodies

Dilution

Company

Anti-Akt

Rabbit polyclonal

1:3000*

Cell Signaling (Temecula, CA,
USA)

Anti-Caspase 3

Rabbit polyclonal

1:1000*

Cell Signaling (Temecula, CA,
USA)

Anti-cleaved Caspase- Rabbit polyclonal
3 (Asp175)

1: 2000*

Cell Signaling (Temecula, CA,
USA)

Anti-ERK

Rabbit polyclonal

1:3000*

Cell Signaling (Temecula, CA,
USA)

Anti-GAPDH

Rabbit polyclonal

1: 2000*

Santa Cruz (Santa Cruz, CA,
USA)

Anti-Glucagon

Mouse polyclonal

1:800

Sigma-Aldrich (St Louis, MO,
USA)

Anti-Glut2

Rabbit polyclonal

1:200

Abcam (Cambridge, MA, USA)

Anti-Insulin

Mouse polyclonal

1:800

Sigma-Aldrich (St Louis, MO,
USA)

Anti-Insulin

Rabbit polyclonal

1:50

Santa Cruz (Santa Cruz, CA,
USA)

Anti-Integrin β1

Rabbit polyclonal

1:500*

Abcam (Cambridge, MA, USA)

Anti-Integrin β1

Rat

1:100

Milipore (Etobicoke, ON, CA)

Anti-Islet-1

Mouse polyclonal

1:100

DSHB (Iowa City, USA)
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Anti-Ki67

Rabbit polyclonal

1:100

Abcam (Cambridge, MA, USA)

Anti-MafA

Rabbit polyclonal

1:100

Bethyl Laboratory
(Montgomery, TX, USA)

Anti-Nkx6.1

Mouse polyclonal

1:100

DSHB (Iowa City, IA, USA)

Anti-p53

Mouse
monoclonal

1:2000*

Cell Signaling (Temecula, CA,
USA)

Anti-pan-Cytokeratin

Mouse
monoclonal

1:50

Santa Cruz (Santa Cruz, CA,
USA)

Anti-Pdx-1

Rabbit polyclonal

1:800

Dr. Wright (University of
Vanderbilt, Nashville, TN,
USA)

Anti-pancreatic
polypeptide

Zymed

1:50

Thermofisher (Waltham, MA,
USA)

Anti-PECAM

Rabbit polyclonal

1:200

Santa Cruz (Santa Cruz, CA,
USA)

Anti-phospho-Akt
(Ser473)

Rabbit polyclonal

1:2000*

Cell Signaling (Temecula, CA,
USA)

Anti-phospho-p53
(Ser15)

Rabbit polyclonal

1:1000*

Cell Signalling (Temecula, CA,
USA)

Anti-phospho-ERK
(Thr202/Tyr204)

Rabbit polyclonal

1:3000*

Cell Signaling (Temecula, CA,
USA)

Anti-Somatostatin

Rabbit polyclonal

1:50

Thermofisher (Waltham, MA,
USA)
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Anti-β-actin

Mouse polyclonal

1:5000*

Sigma-Aldrich (St Louis, MO,
USA)

Dilution

Company

1:1 (no
dilution)

Invitrogen (Carlsbad, CA, USA)

Anti-mouse secondary Goat polyclonal
antibody

1:50

JRL (West Grove, PA, USA)

Anti-rabbit secondary
antibody

1:50

JRL (West Grove, PA, USA)

Secondary
Antibodies
Horseradish
peroxidase-linked
secondary antibodies

Broad Spectrum

Goat polyclonal

*dilution factor for western blot analysis. DSHB (Developmental Studies Hybirdoma
Bank); JRL (Jackson Immunoresearch Laboratories)
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Chapter 3 - Results
3.1 Tamoxifen dosages on fetal body weight, premature birth
rate, and intrauterine death at e19.5.
To determine the effective dosage of tamoxifen on pregnant mice and to induce
an appropriate knockout of β1integrin in fetuses, a single (1x), two (2x), or three (3x)
dose(s) of tamoxifen were given via gavage from e13.5 to e15.5. A higher rate of
premature birth before e19.5 (60% of pregnancies) was observed in the 3x oral tamoxifen
dosage treatment when compared to 1x and 2x groups (Figure 3.1A). The number of
fetuses found dead in utero at e19.5 was also higher in pregnant female mice
administered with 3x tamoxifen dosage (Figure 3.1B), with close to 30% of total
dissected litters displaying abnormal development. The common abnormalities observed
included in utero death, and discoloured or darkened skin. Internal coagulated blood
surrounding the pancreas region was also observed in these irregular fetuses. However,
no difference in fetal body weight and pancreas weight was observed between control
and MIPβ1KO at the time of dissection (e19.5), indicating that the number of tamoxifen
dosages administered did not affect overall body and pancreas weight (Figure 3.1C and
3.1D). Thus, subsequent experiments examined control and MIPβ1KO fetuses with 1x or
2x tamoxifen dosage(s). In addition, we measured fetal blood glucose level and found no
significant difference between the control, MIPβ1KO, and heterozygous circulating blood
glucose level in the 2x tamoxifen group (Figure 3.2A). An ELISA also showed a similar
level in plasma insulin between the control and MIPβ1KO groups (Figure 3.2B).
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Figure 3.1: Different tamoxifen dosages on fetal MIPβ1KO mice premature birth,
intrauterine death rates, body weight, and pancreas weight at e19.5.
(A) Proportion of premature births for all tamoxifen induced pregnant mice (1x n=7, 2x
n=28, 3x n=8 pregnancies per group). (B) Proportion of intrauterine dead fetuses in each
litter (1x n=7, 2x n=19, 3x n=4 litters per group). (C) Body and (D) pancreas weight of
fetal MIPβ1KO and control mice were measured at the time of fetal dissection (Body: 1x
n=7, 2x n=23, 3x n=5 fetuses per group, Pancreas: n= 13-14 fetal pancreata per group).
Data are expressed as means ± SEM.
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Figure 3.2: Blood glucose and plasma insulin content on fetal MIPβ1KO and control
mice at e19.5 with 2x tamoxifen dosage.
(A). Blood glucose level in control, MIPβ1KO, and heterozygous groups (n=4-9 fetuses
per group). Data are expressed as means ± SEM. (B) Plasma insulin content in control
and MIPβ1KO groups. Data are expressed as means ± SD (n=2 fetuses per group). White
bars, control; grey bars, heterozygous; black bars, MIPβ1KO.
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3.2 Efficiency of b1 integrin knockout in beta-cells of fetal
MIPb1KO mice.
To determine the efficiency of beta-cell β1 integrin knockout,
immunofluorescence and western blot analysis of β1 integrin expression in fetal
pancreata was performed to compare the percentage of knockout achieved with different
tamoxifen administration. About 56% of β1 integrin staining in beta-cells was lost in
MIPβ1KO fetal pancreata administered with 2x tamoxifen dosage when compared to
control fetuses, determined by co- immunofluorescence of β1 integrin and insulin (p <
0.05 vs. controls, Figure 3.3A and 3.3B). However, only a 20% reduction of β1 integrin
staining in MIPβ1KO beta-cells given the 1x tamoxifen dosage was found, indicating a
weaker recombinase activity (p < 0.05 vs. controls, Figure 3.4A). Western blot analysis
of whole fetal pancreas samples showed a significant reduction (56%) in β1 integrin
protein level in MIPβ1KO pancreata administered the 2x tamoxifen dosage (p < 0.05,
Figure 3.3). Pancreata collected from the 3x tamoxifen dosage showed a 50% reduction
in β1 integrin (Figure 3.4B). Since the tamoxifen dosage affects both the efficiency of β1
integrin recombinase activity and toxicity in fetuses, the 2x dosage was selected for all
subsequent experimental studies.
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Figure 3.3: Efficiency of fetal beta-cell specific β1 integrin knockout.
(A) Representative double immunofluorescence image (top) and quantification (bottom)
of β1 integrin+ beta-cells after 2x tamoxifen administration in MIPβ1KO and control
fetuses (n=5 pancreata per group). Scale bar: 25 µm. (B) Representative western blot
image (right) of β1 integrin protein level in fetal MIPβ1KO and control pancreata (n=5
pancreata per group). β1 integrin protein levels were normalized to β-actin as fold vs.
controls. White bar, control (Ctrl); black bar, MIPβ1KO. Data are expressed as mean
±SEM, *p < 0.05, vs. controls.
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Figure 3.4: Efficiency of fetal beta-cell specific β1 integrin knockout with 1x or 3x
tamoxifen dosage(s) between e13.5-15.5.
(A) Representative double immunofluorescence images (top) and quantification (bottom)
of β1 integrin+ beta-cells in MIPβ1KO and control mice with 1x tamoxifen dosage at
e13.5 (n=7-8 pancreata per group). Scale bar: 25 µm. (B) Western blot densitometry for
β1 integrin protein level in fetal MIPβ1KO and control mice treated with 3x tamoxifen
dosage at e13.5-15.5 (n=3 pancreata per group). β1 integrin protein levels were
normalized to β-actin and expressed as fold vs. controls. White bar, control; black bar,
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3.3 Fetal MIPb1KO mice display smaller islets, loss of betacell mass, and decreased beta-cell proliferation at e19.5.
Immunofluorescence staining was performed on fetal pancreata to determine if
the development of beta-cell mass was affected by the loss of β1 integrin in MIPβ1KO
mice. The islet architecture was unchanged between control and MIPβ1KO groups, with
clusters of insulin+ cells surrounded by glucagon+ cells observed in both fetal groups
(Figure 3.5A). The morphometric analysis of islet density (islets per mm2) showed a
significant reduction in MIPβ1KO pancreata when compared to controls (p < 0.05, Figure
3.5B) The islet area (the combined glucagon+ & insulin+ area) was also significantly
decreased in MIPβ1KO mice (p < 0.05 vs. controls, Figure 3.5C). The decrease in islet
area was due to a significant reduction in both beta-cell area and mass in the MIPβ1KO
mice, and not due to changes in the alpha-cell compartment of the islet (Figure 3.5F and
G). The findings indicate that the knockout of β1 integrin in beta-cells affects the
development of normal beta-cell mass with no impact on alpha-cell mass.
To assess whether the loss of beta-cell mass is associated with beta-cell
replication, the proliferation of beta-cells was examined using double
immunofluorescence staining. A significant reduction of Ki67+/insulin+ cells was
observed in the islets of MIPβ1KO pancreata when compared to controls (p < 0.05,
Figure 3.6), indicating that normal β1 integrin signal is necessary for maintaining betacell proliferation and adversely impacts the developing beta-cell mass.
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Figure 3.5: Fetal MIPβ1KO mice display reduced beta-cell mass with unchanged
alpha-cell mass at e19.5.
(A) Representative double immunofluorescence images for glucagon (green) and insulin
(red) staining in the islets of control and MIPβ1KO mice after 2x tamoxifen
administration. Scale bar: 50µm. Nuclei labeled with DAPI (blue). (B) Islet density
(islets/mm2), (C) percent islet area, (D) percent beta-cell area, (E) beta-cell mass, (F)
percent alpha-cell area and (G) mass relative to whole pancreatic section area in control
and MIPβ1KO mice (n=6 pancreata per group). White bar, control; black bar, MIPβ1KO.
Data are expressed as means ± SEM. *p < 0.05, vs. controls.
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Figure 3.6: Fetal MIPβ1KO mice show decreased beta-cell proliferation.
(A) Representative double immunofluorescence images of Ki67+ (green) and insulin+
(red) cells in MIPβ1KO and control pancreatic sections with 2x tamoxifen administration.
Nuclei labeled with DAPI (blue). White arrows indicate double positive cells. Scale bar:
25 µm. (B) Quantification of Ki67+ beta-cells in MIPβ1KO and control islets (n=6
pancreata per group). White bar, control; black bar, MIPβ1KO. Data are expressed as
means ± SEM. *p < 0.05 vs. controls.
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3.4 Fetal MIPb1KO pancreata displayed reduced Pdx-1 or
insulin co-localization with ductal-cell marker.
Pdx-1 is present in early developing pancreatic duct cells as a pancreatic
progenitor cell and is also present in differentiated beta-cells as a key regulator for insulin
gene expression (Du et al., 2009). To determine whether knockout of β1 integrin
influences nascent Pdx-1+ cell populations in the ductal region and their migration into
islet clusters, immunofluorescence staining for Pdx-1 with ductal marker pan-CK was
evaluated (Figure 3.7A). The numbers of Pdx-1+/pan-CK+ cells in total Pdx-1+ cell
clusters (p < 0.05, Figure 3.7B) and pan-CK+ ductal regions (p < 0.05, Figure 3.7C) were
reduced in MIPβ1KO pancreas compared to controls. This suggests that the formation of
pancreatic progenitor Pdx-1+ cells near the ductal region are impacted by β1 integrin loss.
Insulin+ co-staining with pan-CK+ cells was also assessed to confirm that the
emerging Pdx-1+ cells were beta-cells and not another population of islet endocrine cells.
Similar results were observed with the co-localization of insulin+/pan-CK+ beta-cells in
MIPβ1KO ductal and islet clusters (p < 0.05, Figure 3.8A and B). This data further
verified that the loss of β1 integrin in the developing pancreas could impair potential
beta-cell differentiation from Pdx-1+ cells and reduce the formation of new beta-cells
along with their migration into the islet clusters.
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Figure 3.7: Characterization of co-stained Pdx-1 and pan-CK cells in the islet and
ductal cells of fetal MIPβ1KO mice after 2x tamoxifen administration.
(A) Representative double immunofluorescence images of ductal cell marker pan-CK
(green) and pancreatic progenitor Pdx-1 (red) cells. White arrows indicate Pdx-1 nuclear
localization in pan-CK+ ductal cells. Scale bar: 25 µm. (B) Quantification of Pdx-1+/panCK+ cells in total Pdx-1+ cells. (C) Quantification of Pdx-1+/pan-CK+ cells in total panCK+ cells. White bar, control; black bar, MIPβ1KO. Data are expressed as means ± SEM
(n = 4 pancreata per group). *p < 0.05, vs. controls.
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Figure 3.8: Characterization of insulin and pan-CK co-localized cells in the islet and
ductal cells of fetal MIPβ1KO mice after 2x tamoxifen administration.
(A) Representative double immunofluorescence images of pan-CK (green) and insulin
(red). White arrows indicate insulin co-staining with pan-CK. Scale bar: 25 µm. (B)
Quantification of insulin+/pan-CK+ cells in total insulin+ cells. (C) Quantification of
insulin+/pan-CK+ cells in total pan-CK+ cells. White bar, control; black bar, MIPβ1KO.
Data are expressed as means ± SEM (n = 4 pancreata per group). *p < 0.05, vs. controls.
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3.5 Fetal MIPb1KO islets expressed transcription factors
necessary for beta-cell identity.
Morphological and proliferative changes in the MIPβ1KO pancreas may signify
potential changes to transcription factors that are important for the development and
function of beta-cells. The effects of β1 integrin loss on beta-cell identity during pancreas
development were determined using immunofluorescence and immunohistochemistry
staining approaches.
Qualitative comparison of control and MIPβ1KO pancreatic sections revealed that both
groups had similar levels of nuclear TFs Pdx-1, Nkx6.1 and Isl-1 in insulin+ cells (Figure
3.9). Nuclear staining for MafA also showed similar expression in both pancreatic
sections (Figure 3.9). These staining data indicate that beta-cell identity is maintained
throughout the second transition stage of pancreas growth despite the loss of β1 integrin.
Glucose transporter 2 (Glut-2) is the major glucose transporter in mouse beta-cells
and is required for glucose uptake and glucose-stimulated insulin secretion (GSIS) in
both adult and neonatal pancreata (Sansbury et al., 2012; Thorens et al., 1992). The
expression of Glut-2 in insulin+ cells was similar in intensity between control and
MIPβ1KO islets, although MIPβ1KO islets were smaller (Figure 3.10A). Since beta-cell
specific β1 integrin knockout does not change beta-cell identity, the delta (somastostatin)
and gamma (pancreatic polypeptide) cells were assessed in fetal islets to determine if
other endocrine cell fates were affected. Qualitative immunofluorescence analysis also
confirmed that control and MIPβ1KO islets contained similar level of both endocrine cell
populations within islet clusters (Figure 3.10B and C).
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Figure 3.9: Fetal MIPβ1KO islets expressed transcription factors necessary for betacell identity.
Representative double immunofluorescence images showing that insulin+ cells (red) of
both MIPβ1KO and control pancreata display nuclear localization of transcription
markers (A) Pdx-1, (B) Nkx6.1, and (C) Islet-1 (green) after 2x tamoxifen administration.
DAPI, blue. (D) Immunohistochemical staining demonstrates similar levels of MafA
(red) in both experimental groups. Nuclei were labeled with hematoxylin (purple). Scale
bar: 25 µm. (n=3 pancreata per group)
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Figure 3.10: Fetal MIPβ1KO islets displayed endocrine cell identity.
Representative double immunofluorescence images showing (A) Glut 2, (B)
Somatostatin, and (C) pancreatic polypeptide (green) with beta-cell staining (Insulin, red)
for endocrine identity of both MIPβ1KO and control pancreata after 2x tamoxifen
administration. DAPI, blue. Staining demonstrates similar levels in both experimental
groups (n=3 pancreata per group). Scale bar: 25 µm
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3.6 Fetal MIPb1KO mice displayed decreased
vascularization
Islet vasculature is required for normal islet growth and function. Maintenance of
the islet vascular endothelial cell population is essential for the formation of the basement
membrane in close proximity to beta-cells, which contributes to their proliferation and
function through β1 integrin - laminin activation (Nikolova et al., 2006). To assess
whether loss of beta-cell β1 integrin affected the contribution of islet vascularization to
beta-cell mass, morphological analysis of islet vascularization with double
immunostaining for PECAM-1+ and insulin+ was used to determine the islet capillary
area and density (Figure 3.11A). MIPβ1KO pancreas sections displayed a lower area of
islet vascularization (islet capillary area in total islet area) compared to controls (p <
0.05, Figure 3.11B). The density of capillaries in MIPβ1KO islets was also reduced (p <
0.05, Figure 3.11C). These findings are consistent with the concept that the islet
microvasculature may affect beta-cell proliferation and supports the interaction between
the ECM, endothelial cells, and beta-cells via β1 integrin in promoting beta-cell mass.
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Figure 3.11: Fetal MIPβ1KO pancreata displayed decreased vascularization.
(A) Representative co-immunofluorescence images show decreased vascularization
(PECAM-1, green) in the pancreatic islets (Insulin, red) of MIPβ1KO and control mice
after 2x tamoxifen administration. White arrows indicate PECAM-1+ cells. Scale bar: 25
µm. Quantification of immunofluorescence images for (B) the percent of PECAM-1+ area
over total islet area and (C) islet vessel density (n = 4-5 pancreata per group). White bars,
control; black bars, MIPβ1KO. Data are expressed as means ± SEM. *p < 0.05 vs.
controls.
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3.7 Downstream b1 integrin signaling in the MIPb1KO
pancreas
Since decreased beta-cell mass and proliferation were observed in fetal MIPβ1KO
mice, downstream β1 integrin signalling pathways involved in cell proliferation were
investigated. Western blot analysis displayed a downregulation of ERK1/2 signalling
indicated by a decrease in phosphorylated ERK1/2 (p<0.05 vs. controls, Figure 3.12A).
Akt is also a part of the integrin downstream signalling cascade and plays a role in betacell survival. However, same for signaling mark phosphorylated AktS473 levels were
unchanged in MIPβ1KO pancreata when compared to controls (Figure 3.12B). Akt
activation has been shown to decrease apoptosis by inhibiting downstream p53 activation.
Correlating with unchanged phosphorylated Akt levels, phosphorylated p53 levels were
also similar in levels between MIPβ1KO and control pancreata (Figure 3.12C). Apoptotic
activity marked by cleaved caspase-3 level were also not altered (Figure 3.12D). Taken
together, intracellular signaling pathways in MIPβ1KO beta-cells indicate reduced
proliferation and neogenesis with unchanged levels of apoptotic activity.
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Figure 3.12: Downstream β1 integrin signaling pathway analysis.
Western blot analyses for (A) phospho- and total-ErkT202/Y204, (B) phospho- and totalAktS473, (C) phospho- and total-p53Ser15 and (D) cleaved and total caspase-3 (n = 4
pancreata per group) in fetal control and MIPβ1KO pancreata after 2x tamoxifen
administration. Representative blotting images are shown. White bars, control; black
bars, MIPβ1KO. Data are normalized to control and expressed as means ± SEM. *p <
0.05.
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Chapter 4 - Discussion
This study examined the in vivo role of beta-cell β1 integrin in pancreatic
endocrine cell development using a temporally tamoxifen-induced MIPβKO mouse
model. Compared to other β1 integrin KO studies that utilized the Cre recombinase
system in congenital RIPβ1KO and adult MIPβ1KO models, this project focuses on the
loss of β1 integrin at the beginning of the second transition stage of embryonic pancreas
growth. MIPβ1KO fetal pancreata demonstrated a decrease in beta-cell mass,
proliferation, ERK signaling, and islet vascularization. In addition, formation of nascent
and new beta-cells in the ductal region were impaired in MIPβ1KO fetal pancreas.
However, key TF expression required for normal islet development was not affected.
Taken together, this study suggests that beta-cell β1 integrin is required for expanding
beta-cell growth during their differentiation and maturation in the second stage of
pancreatic development.

4.1 Frequency of tamoxifen administration on the degree of
β1 integrin knockout in MIPβ1KO beta-cells.
The specificity of Cre recombinase activity within beta-cells of MIPCreERT mice
was verified in our lab previously by crossing the mouse line with B6.CgGt(ROSA)26Sor

tm9(CAG-tdTomato)Hze
/J reporter mice (Trinder et al., 2016). An initial

tamoxifen dosage of 6 mg/ 40 g bodyweight was given for a single day at e13.5 to induce
knockout in MIPβ1KO fetal mouse. This method was adapted from Trinder et al. (2016),
where 75% of insulin receptor knockout was observed through western blot. This study
examined the oral gavage route instead of the single intraperitoneal (I.P.) used in
pregnant dams from Trinder et al. (2016), and knockdown efficiency with this route was
assessed using different dosages. Oral gavage was selected over I.P. injection due to the
higher toxic effect on the pregnant dam observed with earlier I.P. injection experiments.
1x tamoxifen dosage at e13.5 only induced a 20% loss in beta-cell β1 integrin when
compared to the 2x dosage at e13.5 and e15.5 (56% knockout). This level of β1 integrin
knockout was similar to the knockout achieved in I.P. –administered postnatal MIPβ1KO
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(60% knockout) (Peart et al., 2017). This suggests that both routes of tamoxifen
administration are an acceptable form of inducing β1 integrin knockout in the beta-cell
target, but the dosage frequency received for successful in utero recombination is
dependent on the administration route used where in our study, the oral gavage route
required a higher dosage frequency.
Administering the 3x tamoxifen dosage from e13.5 to e15.5 produced a 50% loss
in beta-cell β1 integrin. Consecutive administration of high tamoxifen concentrations was
shown to produce adverse effects during pregnancy as higher instances of premature birth
and intrauterine fetus death were observed. A higher proportion of abnormal birth
observed with the 3x tamoxifen dosage was not specific to the MIPβ1KO genotype,
suggesting that irregular fetus growth was due to the adverse effects from tamoxifen and
not due to beta-cell β1 integrin knockout. This may indicate a dose-dependent toxicity
effect with tamoxifen administration similar to previous reports that utilize tamoxifen
(Bersell et al., 2013; Denk et al., 2015). Considering the efficiency of β1 integrin
knockout between the three tamoxifen dosages and the toxicity effect on fetuses, the 2x
tamoxifen dosage was demonstrated to be the most appropriate dosage for our study and
was selected for all subsequent studies.

4.2 Beta-cell specific β1 integrin knockout on beta-cell mass
and proliferation.
Even with similar body and pancreas weight between MIPβ1KO and littermate
controls, quantitative analysis of islet morphology showed a significant reduction in betacell mass and area, as well as total islet area, for MIPβ1KO fetuses by the end of the
second transition stage. This is similar to previous studies with congenital beta-cell β1
integrin knockout using RIP-driven Cre recombinase (Diaferia et al., 2013) or when
knockout was induced in 4-week old MIPβ1KO adult mice (Peart et al., 2017). Along
with the decrease in beta-cell mass, overall islet density was reduced in the MIPβ1KO
pancreas, which was also found in earlier studies (Diaferia et al., 2013; Peart et al., 2017).
Since the MIPβ1KO alpha-cell mass and area were unaffected, the loss of overall islet
area was likely due to the significant reduction in beta-cell area and mass. This was also
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consistent with adult MIPβ1KO study with unchanged alpha-cell and a reduction in betacell area (Peart et al., 2017). Adult male mice with a global knockout of β1 integrin in
collagen-producing Col1a2 cells, a major ligand in ECM-β1 integrin interaction,
demonstrated a decrease in beta-cell mass (Riopel et al., 2011). β1 integrin activates the
MAPK/ERK pathway through association with FAK to regulate beta-cell, furthermore,
ablation of FAK in beta cells showed a similar reduction in beta-cell mass (Cai et al.,
2012; Saleem et al., 2009). These results emphasize that β1 integrin expression is
required throughout pre- and postnatal development to maintain beta-cell mass. Since the
second transition stage is largely characterized by beta-cell differentiation and expansion
(Gunasekaran et al., 2012; Habener et al., 2005; Kaung, 1994), the loss of beta-cell β1
integrin during this stage is expected to cause a defect in beta-cell growth. Our data
verified that the loss of b1 integrin from e13.5 led to a reduction of beta-cell mass at
e19.5 in MIPb1KO pancreas, indicating a sensitive in vivo time window during
development that is essential for beta-cell growth. These findings implicate that beta-cell
b1 integrin is important for normal beta-cell mass development during the second
transition stage of pancreas growth.
Cell cycle progression and signaling in MIPβ1KO beta-cells were examined to
determine its contribution to reduced islet density, beta-cell mass, and area. The
FAK/MAPK/ERK signaling cascade has been shown to be activated through β1 integrin
to maintain beta-cell function and growth in vitro (Hammar et al., 2004; Saleem et al.,
2009; Wang et al., 2005) and in vivo models (Cai et al., 2012; Peart et al., 2017; Riopel et
al., 2011). A decrease in beta-cell proliferation and phosphorylation of downstream
signaling molecule ERK1/2 were found in MIPβ1KO fetal pancreata, which is also
similar with previous adult β1KO, MIPβ1KO and congenital RIPβ1KO beta-cell studies
(Diaferia et al., 2013; Peart et al., 2017; Riopel et al., 2013). The impairment in ERK1/2
signaling in MIPβ1KO fetuses during the second transition stage could contribute to
decreased beta-cell proliferation and expansion.
β1 integrin deficiency has also been shown to play a role in the survival of betacells through PI3K and downstream phosphorylation of AktS473 protein, which regulates
anti-apoptotic p53 and pro-apoptotic cleaved caspase-3 protein signaling (Diaferia et al.,
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2013; Peart et al., 2017; Xia et al., 2004). However, western blot analysis in the
MIPβ1KO fetal pancreas did not show a change in phospho-Akt, phospho-p53 or cleaved
caspase-3 activity in the fetal MIPβ1KO pancreas. The unchanged levels of phospho-Akt,
cleaved caspase-3, and phopho-p53 proteins may suggest that β1 integrin signaling
during the second transition stage does not influence cell survival through the Akt
pathway.
Although adult MIPb1KO islets displayed a down-regulation of Akt
phosphorylation with change of cyclin D1 and cleaved PARP (Peart et al., 2017), adult
β1KO mice and β1 integrin blockade in INS-1 studies showed a similar reduction in
phospho-ERK with no change to the Akt phosphorylation (Krishnamurthy et al., 2011;
Riopel et al., 2011). Furthermore, blocking b1 integrin in the human fetal pancreatic cells
also showed down-regulation of ERK pathway with no change in the Akt signaling
pathway (Wang et al, 2005, Saleem et al., 2009). Taken together, our current and
previous in vivo and in vitro studies suggest that β1 integrin signals primarily through the
MAPK/ERK pathway, with no effect on Akt pathway during the second transition stage
of embryonic pancreas development.

4.3 Newly formed beta-cell from the ductal compartment in
MIPβ1KO mice.
Since pancreatic progenitor cells in the ductal epithelium undergo a process of
cell budding, migration, and differentiation to form islet cells clusters during the second
transition stage (Alpert et al., 1988; Gu & Sarvetnick, 1993), MIPβ1KO pancreata were
examined to determine if beta-cell formation in the pancreatic ductal region was also
affected and contributed to the reduced beta-cell mass. Decreased number of Pdx-1+ or
insulin+ ductal cells in both ductal and islet cluster region of fetal MIPβ1KO pancreata
were observed through immunofluorescence staining, indicating that beta-cell β1 integrin
knockout also impaired nascent beta-cells in the pancreatic ductal region. Previously,
aVβ1 integrin expression has been shown as a requirement for fetal pancreatic beta-cell
spreading and migration during islet neogenesis (Kaido et al., 2010). This may indicate
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that beta-cell knockout of β1 integrin impaired the formation of both pancreatic
progenitor (Pdx-1+) and beta-cells (insulin+) in the ductal epithelium.
In addition, integrin-matrix interactions for αvβ5 and αvβ3 through vitronectin
and fibronectin has been shown to be required for emerging islet cells from fetal ductal
epithelium (Cirulli et al., 2000) , and both vitronectin and fibronectin are major β1
integrin-ECM associated ligands. Therefore, a possible reduction in beta-cell β1 integrin
interaction with these key associated ligands in the MIPβ1KO may have affected the
differentiation or emergence of Pdx-1+ and insulin+ cells in the ductal epithelium. These
results may suggest that reduced beta-cell mass in fetal MIPβ1KO pancreata is due to a
combination of decreased beta-cell proliferation and formation of nascent endocrine cell
in the ductal compartment during the second transition stage.

4.4 Endocrine and beta-cell specific transcription factors in
MIPβ1KO mice.
We examined if fetal MIPβ1KO beta-cells had altered expression of TFs
necessary for proper beta-cell development. Pdx-1 is an important TF that maintains betacell identity, growth, and survival (Brissova et al., 2006; Gittes, 2009; Offield et al.,
1996). Previous Pdx-1 gene mutation studies have shown hindered pancreatic
development and a loss of differentiation in pancreatic progenitors and beta-cells (Guo et
al., 2013; Jonsson et al., 1994; Offield et al., 1996). A decrease in beta-cell Pdx-1 was
also observed in the adult β1KO studies with postnatal β1 integrin knockout (Peart et al.,
2017; Riopel et al., 2011). Since adult β1KO mice displayed a decrease in insulin content
and glucose intolerance, reduced beta-cell Pdx-1 expression is more likely to be
associated with its role for insulin synthesis and glucose metabolism in the mature β1KO
pancreas. However, qualitative assessment of Pdx-1 appears to be unchanged in fetal
MIPβ1KO beta-cells, which is similar to the findings from congenital RIPβ1KO mice
(Diaferia et al., 2013). Even with the observed reduction of Pdx-1+ cells in the ductal
region, unchanged MIPβ1KO Pdx-1 expression in the beta-cell may suggest that β1
integrin knockout does not affect beta-cell identity once the islet cluster is formed during
the second transition stage of pancreatic growth. Expression of TFs MafA, Islet-1, and
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Nkx6.1 are also required during development for beta-cell maturation (AguayoMazzucato et al., 2013; Bonner-Weir et al., 2016; Sander et al., 2000). Our study showed
no change in nuclear expression of these transcription factors between fetal MIPβ1KO
and the control islets, which was similar to the congenital RIPβ1KO study (Diaferia et al.,
2013). This may also suggest that beta-cell β1 integrin knockout did not affect the
expression of other major TFs needed for beta-cell development during the second
transition stage.

4.5 Islet vascularization in MIPβ1KO mice.
Islet vascularization is important for maintaining beta-cell function (Brissova et
al., 2006; Lammert et al., 2003). The angiogenic promoting factor, Vegf, is secreted by
beta-cell and attracts vascular endothelial cell formation close to the endocrine clusters
(Inoue et al., 2002; Lecouter et al., 2001; Watada, 2010). Laminin in the basement
membrane of nearby endothelial cells has been found to interact with beta-cell β1 integrin
and promote beta-cell proliferation and insulin expression (Nikolova et al., 2006). Our
study showed a significant decrease in islet vessel density and islet capillary area in fetal
MIPβ1KO islets. This is consistent to the Riopel et al. (2011) β1KO study where a
similar reduction in adult islet capillary area was observed. During the second transition
stage of pancreas development, reduced beta-cells mass in MIPβ1KO mice may have
impaired Vegf production, leading to reduced nearby endothelial cell formation and
overall islet vascularization (Nikolova et al., 2006). This result may further provide
support that β1 integrin is required for islet vascularization in fetal MIPβ1KO pancreata
during the second transition stage of pancreas development.

4.6 Limitation of this study
Fetal MIPβ1KO during the second transition stage of pancreas development
currently shows a significant decrease in islet vascularization. However, determining
potential changes in Vegf-a of MIPβ1KO beta-cells was unsuccessful due to the quality
of isolation which appeared to be protein specific. A similar issue was encountered with
assessing phosphorylated-FAK levels, which would have contributed towards
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understanding the FAK/MAPK/ERK pathway during this stage of development. Our
study showed a reduction in nascent beta-cell population in the ductal and islet clusters,
however, the reason for this impairment was not fully determined to be from the
migration and/or immediate cell death of the newly formed beta-cells. Unfortunately,
there was also a significant difficulty in obtaining a larger fetal pancreas sample which
may have potentially skewed the data.
Studies that focused on the postnatal development of MIPβ1KO mice was
attempted to determine if the loss of beta-cell β1 integrin during the second transition
stage affected beta-cell remodeling and function in the adult mice. However, tamoxifen
administration to pregnant dams led to either infanticide or neglect towards the newborn
litters. Tamoxifen and/or handling during the gestational period may have caused an
adverse effect on pregnant mothers’ behaviour and health. Cross-fostering with
tamoxifen-free mothers has been implemented but has also demonstrated minimal
success due to persistent litter neglect.

4.7 Conclusion and future direction
This study demonstrated the temporal role of beta-cell b1 integrin during the
second transition stage of murine pancreas development. MIPb1KO mice had a reduction
in beta-cell mass and area. Loss in MIPb1KO beta-cells was due to decreased beta-cell
proliferation, ERK signalling, and formation of nascent Pdx-1+ cells and beta-cells from
the ductal epithelium, with an overall reduction in intraislet vascularization. This study
may improve our understanding of b1 integrin role in beta-cell differentiation during the
critical pancreatic developmental window.
Since our study only displayed a decrease in emerging Pdx-1+ and insulin+ beta-cell in
the ductal region, real-time migration of these nascent beta cells was not investigated.
Utilizing in vivo time-based microscopy with fluorescent labelling to mark nascent betacell movement towards islet clusters would determine migration defects in MIPb1KO
mice during the second transition stage of pancreas morphogenesis.
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MIPb1KO mice displayed decreased islet blood vessel formation during the second
transition stage of pancreas development. Since proper vascularization is required for
pancreas growth (Lammert et al., 2001; 2003; Magenheim et al., 2011), investigating
MIPb1KO beta-cell Vegf and islet endothelial laminin expression could build on the
working model for b1 integrin-vasculature interaction during beta-cell growth (Nikolova
et al., 2006).
Formation of new fetal and neonatal beta-cells during the third transition stage is largely
from neogenesis, while new adult beta-cells are produced through replication (Scaglia et
al., 1997). b1 integrin knockout at the beginning of the second transition stage of
pancreas development showed decreased beta-cell mass by the end of this stage. Further
examining the pancreatic growth of these mice throughout the neonatal and postnatal
stages would allow us to determine if islet morphological changes due to b1 integrin
knockout at the second stage of transition impairs adult beta-cell function. This study has
shown that beta-cell b1 integrin is important during the second transition stage of
pancreas development which may provide future direction towards beta-cell cell
adhesion’s role in pancreas growth.
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